Jul 28, 2022
Researchers released a study that has identified the first biochemical marker that could help detect babies more at risk of Sudden Infant De
seen from Germany
seen from United Kingdom
seen from Spain
seen from China
seen from United Kingdom
seen from China
seen from United Kingdom
seen from Italy
seen from Mexico
seen from Taiwan
seen from United States
seen from China
seen from Yemen
seen from Singapore
seen from China
seen from China
seen from Bangladesh
seen from United Kingdom
seen from France
seen from Malaysia
Researchers released a study that has identified the first biochemical marker that could help detect babies more at risk of Sudden Infant De
A newly discovered memory in our bones: Blood stem cells boost immunity by keeping a record of previous infections.
A new study shows that blood stem cells keep a record of previous infections on their DNA to produce a rapid response when infections return. The discovery could help to develop novel vaccines and immunotherapies. Thoughts health innovators?
It is known that stem cells contained within the human body can differentiate into many different types of cells, in some cases regenerating or repairing tissue. Hematopoietic stem cells (HSCs), commonly known as blood stem cells, are found in the bone marrow where they produce platelets, red blood cells, and white blood cells which are also known as the cells of the immune system. Even though…
View On WordPress
Noninvasive eye scan can detect key signs of Alzheimer's Disease in humans.
Noninvasive eye scan can detect key signs of Alzheimer’s Disease in humans.
Alzheimer’s disease (AD) is an invariably fatal neurodegenerative disorder and the leading cause of senile dementia worldwide. There is no effective treatment and limited functionality for early unequivocal diagnosis. Now, a study led by researchers at Cedars-Sinai provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer’s. The team state…
View On WordPress
Cell-free DNA Methylation Analysis, a Noninvasive Biomarker for Detection, Prediction, Classification, and Treatment Monitoring for Brain Tumors - Research
Background and objective: Brain tumors represent a major clinical challenge due to difficulties in early detection and precise molecular characterization. Recent advances in liquid biopsy have highlighted cellfree DNA (cfDNA) methylation profiling as a promising non-invasive approach for the detection, classification, prognostication, and longitudinal monitoring of brain tumors. Methods: A…
FDX1 as a predictive biomarker and therapeutic target for lymph node metastasis in gastric cancer - Research
The prognostic values of cuproptosis-related genes (CRGs) in gastric cancer with lymph node metastasis (GCLM), especially in the tumor immune microenvironment (TIME), remain unclear. We analyzed the expression, mutation, immunity, drug sensitivity, and prognostic value of CRGs in GCLM using TCGA and GEO cohorts. Consensus clustering was performed to identify CRG subtypes, with differences…
NSUN2 as an emerging epigenetic regulator in cancer: from biomarker to therapeutic target - Research
NOL1/NOP2/SUN domain family member 2 (NSUN2), a member of the RNA methyltransferase family responsible for catalysing 5-methylcytosine (m5 C) modifications, has been increasingly recognized as a key regulatory factor in the initiation and progression of cancer. A growing body of evidence indicates that NSUN2 is aberrantly expressed in multiple malignancies, such as hepatocellular carcinoma,…
Clinical and immunological significance of FOXO1 as a biomarker of improved response to immune checkpoint plus tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma - Research
Background: Predicting response to immune checkpoint inhibitor plus tyrosine kinase inhibitor (IO+TKI) therapy in metastatic renal cell carcinoma (mRCC) remains challenging. Forkhead box protein O1 (FOXO1) is a key transcription factor regulating tumor suppression and T cell immunity, but its clinical and immunological significance in RCC is unclear. Methods: FOXO1 expression was analyzed in…
The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights - Research
Osteosarcoma, the most aggressive primary malignant bone tumor, has stagnant therapeutic outcomes despite decades of standard MAP chemotherapy and surgery; 5-year overall survival (OS) is <30% for metastatic/recurrent cases. Plagued by genomic heterogeneity, immunosuppressive TME, and low immunogenicity, emerging immunotherapies lack robust large-scale clinical validation. We systematically…